Effect of Sparsentan Versus Irbesartan With Genetic FSGS | Docwire News
Researchers evaluated the efficacy of sparsentan in a subset of patients with genetic focal segmental glomerulosclerosis.
Related Articles
MediBeacon Nabs FDA Approval for TGFR System to Assess Kidney Function | Docwire News
The FDA has approved MediBeacon’s Transdermal GFR (TGFR) system to evaluate kidney function.
TaxProf Blog: SCOTUSblog Founder Tom Goldstein Hit With 22-Count Federal Tax Evasion Indictment
National Review, The Wild Indictment of Tom Goldstein of SCOTUSBlog: You might think that Tom Goldstein would be enjoying the pinnacle of respectability in the…
Stop Overregulating Research — The James G. Martin Center for Academic Renewal
The newly inaugurated second Trump administration has arrived, and among the changes that the president and his allies have proposed is large-scale simplification and elimination…
Call for Submissions: Quiz
Every month, AJKD features an image-based Quiz that tests readers’ acumen in resolving a diagnostic or therapeutic dilemma. All Quizzes are freely available in an online…
Identification of Modifiable Factors Associated With Fatigue and Dialysis Recovery Time | Docwire News
A study identified modifiable dialysis-related factors associated with fatigue and dialysis recovery time so that they might be addressed in future trials.
American Society of Nephrology | Member Services – Home
Take advantage of the benefits of ASN membership. Join ASN or renew membership online.
Finerenone: Completing the Cardiorenal Guideline-Directed Medical Therapy?
“Finerenone: Completing the Cardiorenal Guideline-Directed Medical Therapy?” published on 08 Jan 2025 by American Society of Nephrology.